{
    "nctId": "NCT00434447",
    "briefTitle": "Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases",
    "officialTitle": "A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety",
    "overallStatus": "COMPLETED",
    "conditions": "Bone Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 73,
    "primaryOutcomeMeasure": "Safety assessed by incidence of renal impairment, osteonecrosis of the Jaw (ONJ), adverse events and serious adverse events. Efficacy assessed by incidence of skeletal related events (SREs).",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Documented bone metastases from breast cancer, prostate cancer or multiple myeloma\n* Prior treatment with zoledronic acid for 1-2 yrs\n* Life expectancy of at least 6 months\n\nExclusion criteria:\n\n* Prior treatment with bisphosphonates other than zoledronic acid\n* Abnormal kidney function\n* Current or previous dental problems or planned dental surgery\n* Pregnant or likely to become pregnant during the study\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}